H. Kim Lyerly

Daniel Nussbaum, MD, is one of 12 investigators to have been selected by National Cancer Institute for their Early-Stage Surgeon Scientist Program (ESSP).

The hybrid retreat showcased the latest gastric cancer, blood cancer, pediatric sarcoma, glioblastoma, breast cancer, and immune micro-environment research.

DCI member H. Kim Lyerly, MD, and pediatric neuro-oncologist Daniel Landi, MD, are co-leaders on the new cross-institutional project.

Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured by the media, academic trade publications & journals.

Here are some of the Duke Cancer Institute faculty, researchers, and clinical providers whose work has recently been featured by the media, academic trade publications & journals.

Here are some of the DCI faculty, researchers and nurses whose work has recently been featured by the media, academic trade publications & journals.

DCI oncologists and researchers are supporting the Komen mission “for a cure” — fighting breast cancer on all fronts. Learn about their research.

A vaccine for HER2-positive breast cancers that is being tested in a clinical trial at DCI is part of an effective, two-drug strategy for enlisting the immune system to fight tumors.

Lyerly, Hartman spinout company Replicate Bioscience and Immunomic Therapeutics form collaboration to combat infectious diseases and cancers.

Here's a sample of some of the DCI physicians, physician-scientists, researchers and nurses whose work is featured by the media and in academic journals.

DCI researchers have observed how stem cell mutations quietly arise and spread throughout a widening field of the colon until they eventually predominate and become a malignancy.     

The mainstay drug trastuzumab could benefit from another antibody to remove roadblocks.